Reversible myocardial dysfunction in sepsis and ischemia

Critical Care Medicine

Volumn 33, Issue 12, 2005, Pages 2845-2847

  Kan, Hong ^a   Failinger, Conard F ^a   Fang, Qiujuan ^a   Finkel, Mitchell S ^a  

^a WEST VIRGINIA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Hibernating myocardium; Ischemic preconditioning; Lipopolysaccharide tolerance; Myocardial depression; Nitric oxide; Sepsis

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE;

ACUTE HEART INFARCTION; CLINICAL FEATURE; DIAGNOSTIC IMAGING; DISEASE ASSOCIATION; DOG; EDITORIAL; HEART CATHETER; HEART INFARCTION PREVENTION; HEART MUSCLE ISCHEMIA; HEART MUSCLE REPERFUSION; HEART MUSCLE REVASCULARIZATION; METABOLIC REGULATION; MYOCARDIAL HIBERNATION; NON INVASIVE MEASUREMENT; NONHUMAN; OPEN HEART SURGERY; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SEPSIS;

EID: 29144501179     PISSN: 00903493     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.CCM.0000190906.89407.36     Document Type: Editorial

References (45)

1. Levy RJ, Piel DA, Acton PD, et al: Evidence of myocardial hibernation in the septic heart. Crit Care Med 2005; 33:2752-2756
2. Heyndrickx GR, Millard RW, McRitchie RJ, et al: Regional myocardial functional and electrophysiological alterations after brief coronary artery occlusion in conscious dogs. J Clin Invest 1975; 56:978-985
3. Braunwald E, Kloner RA: The stunned myocardium: Prolonged, postischemic ventricular dysfunction. Circulation 1982; 66:1146-1149
4. Braunwald E, Rutherford JD: Reversible ischemic left ventricular dysfunction: Evidence for the "hibernating myocardium." J Am Coll Cardiol 1986; 8:1467-1470
5. Rahimtoola SH: The hibernating myocardium. Am Heart J 1989; 117:211-221
6. Reilly JM, Cunnion RE, Burch-Whitman C, et al: A circulating myocardial depressant substance is associated with cardiac dysfunction and peripheral hypoperfusion (lactic acidemia) in patients with septic shock. Chest 1989; 95:1072-1080
7. Parillo JE: Mechanisms of disease: Pathogenic mechanisms of septic shock. N Engl J Med 1993; 328:1471-1477
8. Parker MM, Shelhamer JH, Bacharach SL, et al: Profound but reversible myocardial depression in patients with septic shock. Ann Intern Med 1985; 100:483-490
9. Kumar AR, Brar R, Wang P, et al: Role of nitric oxide and cAMP in human septic serum-induced depression of cardiac myocyte contractility. Am J Physiol 1999; 276:R265-R276
10. Smith LW, McDonough KH: Inotropic sensitivity to β-adrenergic stimulation in early sepsis. Am J Physiol 1988; 255:H699-H703
11. Finkel MS: Effects of pro-inflammatory cytokines on the contractility of mammalian heart. Heart Fail Rev 1996; 1:203-210
12. Kan H, Finkel MS: Interactions between cytokines and neurohormonal systems in the failing heart. Heart Fail Rev 2001; 6:119-127
13. Kan H, Finkel MS: Inflammatory mediators and reversible myocardial dysfunction. J Cell Physiol 2003; 195:1-11
14. Murry CE, Jennings RB, Reimer KA: Preconditioning with ischemia a delay of cell injury in ischemic myocardium. Circulation 1986; 74:1124-1136
15. Kloner RA, Shook T, Przyklenk K, et al: Previous angina alters in-hospital outcome in TIMI-4. A clinical correlate to preconditioning? Circulation 1995; 91:37-47
16. Ping P, Takano H, Zhang J, et al: Isoform-selective activation of protein kinase C by nitric oxide in the heart of conscious rabbits: A signaling mechanism for both nitric oxide-induced and ischemia-induced preconditioning. Circ Res 1999; 84:587-604
17. Takano H, Tang XL, Qiu Y: Nitric oxide donors induce late preconditioning against myocardial stunning and infarction in conscious rabbits via an antioxidant-sensitive mechanism. Circ Res 1998; 83:73-84
18. Brown JM, Grosso MA, Terada LS: Endotoxin pretreatment increases endogenous myocardial catalase activity and decreases ischemia reperfusion injury of isolated rat hearts. Proc Natl Acad Sci U S A 1989; 86:2516-2520
19. Lowenstein CJ, Dinerman JL, Snyder SH: Nitric oxide: A physiologic messenger. Ann Intern Med 1994; 120:227-237
20. Sugden PH, Clerk A: Stress-responsive mitogen-activated protein kinases (c-Jun N-terminal kinases and p38 mitogen-activated protein kinases) in the myocardium. Circ Res 1998; 83:345-352
21. 2 in the human astrocytoma cell line 1321N1. J Biol Chem 1998; 273:606-612
22. Paine E, Palmantier R, Akiyama SK, et al: Arachidonic acid activates mitogen-activated protein (MAP) kinase-activated protein kinase 2 and mediates adhesion of a human breast carcinoma cell line to collagen type IV through a p38 MAP kinase-dependent pathway. J Biol Chem 2000; 275:11284-11290
23. Luss H, Neumann J, Schmitz W, et al: The stress-responsive MAP kinase p38 is activated by low-flow ischemia in the in situ porcine heart. J Mol Cell Cardiol 2000; 32:1787-1794
24. Obata T, Brown GE, Yaffe MB: MAP kinase pathways activated by stress: The p38 MAPK pathway. Crit Care Med 2000; 28(Suppl):N67-N77
25. ATP channels. Am J Physiol 2001; 280:H1278-H1285
26. Abe J, Baines CP, Berk BC: Role of mitogen-activated protein kinases in ischemia and reperfusion injury. The good and the bad. Circ Res 2000; 86:607-609
27. Mackay K, Mochly-Rosen D: Involvement of a p38 mitogen-activated protein kinase phosphatase in protecting neonatal rat cardiac myocytes from ischemia. J Mol Cell Cardiol 2000; 32:1585-1588
28. Carroll R, Yellon DM: Delayed cardioprotection in a human cardiomyocyte-derived cell line: The role of adenosine, p38MAP kinase and mitochondrial KATP. Basic Res Cardiol 2000; 95:243-249
29. i or Gβγ in adult mouse cardiomyocytes. J Biol Chem 2000; 275:40635-40640
30. i-dependent activation. J Biol Chem 2000; 275:19395-19400
31. Nakano A, Baines CP, Kim SO, et al: Ischemic preconditioning activates MAPKAPK2 in the isolated rabbit heart. Evidence for involvement of p38 MAPK. Circ Res 2000; 86:144-151
32. Yue TL, Wang C, Gu JL, et al: Inhibition of extracellular signal-regulated kinase enhances ischemia/reoxygenation-induced apoptosis in cultured cardiac myocytes and exaggerates reperfusion injury in isolated perfused heart. Circ Res 2000; 86:692-699
33. McFalls EO, Hou M, Bache RJ, et al: Activation of p38 MAPK and increased glucose transport in chronic hibernating swine myocardium. Am J Physiol Heart Circ Physiol 2004; 287:H1328-H1334
34. Nakano A, Cohen MV, Critz S, et al: SB 203580, an inhibitor of p38 MAPK, abolishes infarct-limiting effect of ischemic preconditioning in isolated rabbit hearts. Basic Res Cardiol 2000; 95:466-471
35. Vallance P, Moncada S: Role of endogenous nitric oxide in septic shock. New Horiz 1993; 1:77-86
36. Akaike T, Maeda H: Nitric oxide and virus infection. Immunology 2000; 101:300-308
37. Badorff C, Berkely N, Mehhrotra S, et al: Enteroviral protease 2A directly cleaves dystrophin and is inhibited by a dystrophin-based substrate analogue. J Biol Chem 2000; 275:11191-11197
38. Badorff C, Fichtlscherer B, Rhoads RE, et al: Nitric oxide inhibits dystrophin proteolysis by coxsackieviral protease 2A through S-nitrosylation: A protective mechanism against enteroviral cardiomyopathy. Circulation 2000; 102:2162-2164
39. Zaragoza C, Ocampo C, Saura M, et al: The role of inducible nitric oxide synthase in the host response to Coxsackievirus myocarditis. Proc Natl Acad Sci U S A 1998; 95:2469-2474
40. Oddis CV, Finkel MS: Cytokine-stimulated nitric oxide production inhibits mitochondrial activity in cardiac myocytes. Biochem Biophys Res Comm 1995; 213:1002-1009
41. Kan H, Xie Z, Finkel MS: Norepinephrine stimulated MAP kinase activity enhances cytokine induced nitric oxide production by neonatal rat cardiac myocytes. Am J Physiol 1999; 276:H47-H52
42. Kan H, Xie Z, Finkel MS: TNF enhances NO production by neonatal rat cardiac myocytes through MAP kinase mediated activation of NF-κB. Am J Physiol 1999; 277:H1646-H1646
43. Giuffre A, Sarti P, D'Itri E, et al: On the mechanism of inhibition of cytochrome c oxidase by nitric oxide. J Biol Chem 1996; 271:33404-33408
44. Antunes K, Boveris A, Cadenas E: On the mechanism and biology of cytochrome oxidase inhibition by nitric oxide. Proc Natl Acad Sci U S A 2004; 101:16774-16779
45. Boulos M, Astiz ME, Barus RS, et al: Impaired mitochondrial function induced by serum from septic shock patients is attenuated by inhibition of nitric oxide synthase and poly(ADP-ribose) synthase. Crit Care Med 2003; 31:632-633